FSD Pharma: Developing Novel Solutions for Brain & Inflammatory Disorders

FSD Pharma is bringing innovative neuro and inflammatory disorders therapies to millions of patients in need.

FSD Pharma, with only 38.4 million shares issued/outstanding, is a biotechnology company with three drug candidates in different stages of development.

FSD BioSciences, Inc. (“FSD BioSciences”), a wholly-owned subsidiary, is focused on pharmaceutical research and development of its lead compound, ultra-micronized palmitoyl ethylamine (“PEA”) or FSD-PEA (formerly called FSD-201). Lucid Psycheceuticals Inc. (“Lucid”), a wholly-owned subsidiary, is focused on the research and development of its lead compounds, Lucid-PSYCH (formerly Lucid-201) and Lucid-MS (formerly Lucid-21-302). Lucid PSYCH is a molecular compound identified for the potential treatment of mental health disorders. Lucid-MS is a molecular compound identified for the potential treatment of neurodegenerative disorders.

For more information on FSD Pharma Inc. (CSE: HUGE, NASDAQ: HUGE) please click the request investor info button.